We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Test Predicts Prostate Cancer Recurrence

By HospiMedica staff writers
Posted on 07 Jul 2006
A new prognostic test can help determine whether a prostate cancer patient will have a recurrence of the disease, even if surrounding lymph nodes initially appear negative for cancer, according to a study by researchers the University of Southern California (USC, Los Angeles, USA).

The test "appears to be a very powerful test and better than anything else we know of for predicting recurrence,” said Richard Cote, professor of pathology and urology in the Keck School of Medicine of USC. More...
Patients whose disease is caught in the early stages will do very well, said Prof. Cote.

Cote and his colleagues looked at 3,914 lymph nodes from 180 patients who were staged as having lymph nodes negative for cancer based on standardized histologic evaluation. The lymph nodes were then evaluated for occult metastases using new specific immunohistochemistry tests that can detect cancer on a cell-by-cell level.

The new analysis checks for cells that react with antibodies to cytokeratins and prostate-specific antigen (PSA). The team's testing found occult tumor cells in the lymph nodes of 24 patients whose lymph nodes previously had been diagnosed as cancer-free.

The group then compared cancer recurrence and survival in those patients with the hidden tumor cells versus those without the cells. The presence of occult tumor cells was associated with increased prostate cancer recurrence and decreased survival. In fact, "the outcome for patients with occult tumor cells was similar to those who were identified as having positive lymph nodes at the time of the surgery,” noted Prof. Cote.

Current trials also are using the test to find hidden metastases in lymph nodes and bone marrow for breast and lung cancers. The study appeared in the June 2006 Journal of Clinical Oncology.




Related Links:
University of Southern California

Gold Member
12-Channel ECG
CM1200B
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Fetal Monitor
BT-380
Hybrid Arch Device
Neo EDE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.